N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model.

[1]  G. Tsujimoto,et al.  The short chain fatty acid receptor GPR43 regulates inflammatory signals in adipose tissue M2-type macrophages , 2017, PloS one.

[2]  B. Hudson,et al.  Complex Pharmacology of Free Fatty Acid Receptors. , 2017, Chemical reviews.

[3]  Rockann E. Mosser,et al.  Loss of Free Fatty Acid Receptor 2 leads to impaired islet mass and beta cell survival , 2016, Scientific Reports.

[4]  A. Van der Aa,et al.  Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects , 2016, British journal of clinical pharmacology.

[5]  S. Pandey,et al.  A protocol for amide bond formation with electron deficient amines and sterically hindered substrates. , 2016, Organic & biomolecular chemistry.

[6]  B. Hudson,et al.  Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands* , 2015, The Journal of Biological Chemistry.

[7]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[8]  B. Wicksteed,et al.  An Acetate-Specific GPCR, FFAR2, Regulates Insulin Secretion. , 2015, Molecular endocrinology.

[9]  Rik van der Kant,et al.  GPR43 Potentiates β-Cell Function in Obesity , 2015, Diabetes.

[10]  Stefan Offermanns,et al.  Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes , 2015, Nature Medicine.

[11]  L. Nelles,et al.  Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. , 2014, Journal of medicinal chemistry.

[12]  A. Hopkins,et al.  The role of ligand efficiency metrics in drug discovery , 2014, Nature Reviews Drug Discovery.

[13]  W. Garrett,et al.  The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis , 2013, Science.

[14]  G. Tsujimoto,et al.  The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43 , 2013, Nature Communications.

[15]  Graeme Milligan,et al.  Defining the Molecular Basis for the First Potent and Selective Orthosteric Agonists of the FFA2 Free Fatty Acid Receptor* , 2013, The Journal of Biological Chemistry.

[16]  B. Hudson,et al.  Extracellular Ionic Locks Determine Variation in Constitutive Activity and Ligand Potency between Species Orthologs of the Free Fatty Acid Receptors FFA2 and FFA3* , 2012, The Journal of Biological Chemistry.

[17]  A. M. Habib,et al.  Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2 , 2012, Diabetes.

[18]  Niklas Blomberg,et al.  Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules. , 2011, Bioorganic & medicinal chemistry letters.

[19]  M. Hann.  Molecular obesity, potency and other addictions in drug discovery , 2011 .

[20]  John P. Overington,et al.  Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.

[21]  S. Wong,et al.  The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. , 2010, Bioorganic & medicinal chemistry letters.

[22]  P. Rosenstiel,et al.  G Protein-Coupled Receptor 43 Is Essential for Neutrophil Recruitment during Intestinal Inflammation1 , 2009, The Journal of Immunology.

[23]  T. Ritchie,et al.  The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.

[24]  R. Xavier,et al.  Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43 , 2009, Nature.

[25]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[26]  Yang Li,et al.  Identification and Functional Characterization of Allosteric Agonists for the G Protein-Coupled Receptor FFA2 , 2008, Molecular Pharmacology.

[27]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[28]  Richard Morphy,et al.  The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. , 2006, Journal of medicinal chemistry.

[29]  Ki-Choon Choi,et al.  Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. , 2005, Endocrinology.

[30]  M. Parmentier,et al.  Functional Characterization of Human Receptors for Short Chain Fatty Acids and Their Role in Polymorphonuclear Cell Activation* , 2003, Journal of Biological Chemistry.

[31]  S. Dowell,et al.  The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids* , 2003, The Journal of Biological Chemistry.

[32]  M. Bohlooly-y,et al.  Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. , 2011, American journal of physiology. Endocrinology and metabolism.

[33]  J. Comer,et al.  Lipophilicity measurements by liquid chromatography. , 2006, Advances in chromatography.